BCTX
BriaCell Therapeutics Corp. (NASDAQ)
Healthcare — Biotechnology
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Price History
Fundamentals
| Market Cap | $30.19M |
| P/E Ratio (TTM) | - |
| Forward P/E | -8.90 |
| EPS (TTM) | $-0.84 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -175.25% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 75.7 |
| Beta | 1.64 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $30.00 |
| 52-Week Low | $2.60 |
| 50-Day Avg | $3.50 |
| 200-Day Avg | $6.54 |
| Avg Volume | 201.7K |
| Volume | 174.4K |
Performance Analysis
NEUTRALBCTX presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 12:59 UTC
Back to Screener Export Report